摘要
理想的免疫疗法具有对肿瘤的高度杀伤性和对自身组织机体的无害性,因此被用于治疗高致死性的转移性去势抵抗性前列腺癌。前列腺癌的免疫疗法当前主要包括疫苗疗法、免疫检查点阻断疗法、免疫调节剂疗法以及联合疗法,这些疗法分别通过不同的免疫机制治疗前列腺癌。被称作Sipuleucel-T的疫苗早已被美国食品和药品监督管理局批准治疗转移性去势抵抗性前列腺癌,而其他免疫药物的研究尚在进行。本文对转移性去势抵抗性前列腺癌各种免疫疗法的现状及最新进展进行综述。
The ideal immunotherapy should be highly lethal to the tumor and harmless to the body,therefore it’s applied to the highly fatal metastatic castration-resistant prostate cancer.Immunotherapy for prostate cancer currently includes vaccine therapy,immunocheckpoint blocking therapy,immunomodulator therapy,and combination therapy,which treat prostate cancer through different immune mechanisms.A vaccine called Sipuleucel-T has been approved by the Food and Drug Administration to treat metastatic castration-resistant prostate cancer,while research on other immune drugs is ongoing.This article reviews the current status and recent progress of various immunotherapies for metastatic castration-resistant prostate cancer.
作者
吴尚融
刘冉录
Wu Shangrong;Liu Ranlu(Department of Urology,the Second Hospital of Tianjin Medical University,Tianjin Institute of Urology,Tianjin 300211,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2020年第8期637-640,共4页
Chinese Journal of Urology
关键词
前列腺肿瘤
免疫疗法
疫苗
预后
Prostatic neoplasms
Immunotherapy
Vaccines
Prognosis
